fig12

Figure 12. Schematic illustration of the potential mechanisms underlying combined BET and CDK4/6 inhibition. Palbociclib (PD-0332991), a CDK4/6 inhibitor, regulates GSK3β phosphorylation and activates the Wnt/β-catenin pathway, thereby promoting EMT through the TGFβ/Smad signaling pathway. This process is inhibited by the BET inhibitor JQ1. The combination of PD-0332991 and JQ1 may suppress pancreatic tumor cell growth, migration, invasion, and EMT. BET: Bromodomain and extra-terminal; CDK4/6: cyclin-dependent kinases 4 and 6; EMT: epithelial-to-mesenchymal transition.